Form 13-F position report

GINKGO BIOWORKS HOLDINGS INC C

Reported by VANGUARD GROUP INC

DNA CUSIP 37611X100 Manager CIK 0000102909

Reported 86,735,032 shares, up 57,401,650 (195.7%) from the prior quarter.

Reported value 74.6%; share count 195.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 86,735,032 Quarter-end amount reported
Reported value $206,429,000 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 245528000
2022-03-31 118214000
2022-06-30 206429000
2022-09-30 267930000
2022-12-31 171570964
2023-03-31 147485473
2023-06-30 238639447
2023-09-30 239493769
2023-12-31 224398360
2024-03-31 145993729
2024-06-30 46455679
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for GINKGO BIOWORKS HOLDINGS INC C held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -138,964,041 (-100.0%) 0 $0 2024-11-13
Q2 2024 Added 138,964,041 +13,107,377 (10.4%) < 0.01% $46,455,679 2024-08-13
Q1 2024 Reduced 125,856,664 -6,923,431 (-5.2%) < 0.01% $145,993,729 2024-05-10
Q4 2023 Added 132,780,095 +463,096 (0.3%) < 0.01% $224,398,360 2024-02-14
Q3 2023 Added 132,316,999 +4,016,221 (3.1%) < 0.01% $239,493,769 2023-11-14
Q2 2023 Added 128,300,778 +17,409,445 (15.7%) < 0.01% $238,639,447 2023-08-14
Q1 2023 Added 110,891,333 +9,370,053 (9.2%) < 0.01% $147,485,473 2023-05-15
Q4 2022 Added 101,521,280 +15,646,253 (18.2%) < 0.01% $171,570,964 2023-02-10
Q3 2022 Reduced 85,875,027 -860,005 (-1.0%) < 0.01% $267,930,000 2022-11-14
Q2 2022 Added 86,735,032 +57,401,650 (195.7%) < 0.01% $206,429,000 2022-08-12
Q1 2022 Reduced 29,333,382 -212,725 (-0.7%) < 0.01% $118,214,000 2022-05-13
Q4 2021 New 29,546,107 +29,546,107 (0.0%) < 0.01% $245,528,000 2022-02-14

Who else reported the position

278 managers reported GINKGO BIOWORKS HOLDINGS INC C for Q2 2022.

Managers reporting GINKGO BIOWORKS HOLDINGS INC C in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAILLIE GIFFORD & CO Added 205,327,786 +37,575,106 0.5% $488,680,000 4 qtrs
ARK Investment Management LLC Added 87,358,057 +22,824,417 1.59% $269,063,000 4 qtrs
VANGUARD GROUP INC This report Added 86,735,032 +57,401,650 < 0.01% $206,429,000 3 qtrs
GENERAL ATLANTIC L P Reduced 69,435,733 -21,375,081 2.16% $165,257,000 4 qtrs
Anchorage Capital Group L L C Unchanged 69,158,354 0 16.46% $164,597,000 4 qtrs
MORGAN STANLEY Added 39,213,029 +14,233,562 0.01% $93,329,000 4 qtrs
BlackRock Inc Added 32,353,263 +16,399,997 < 0.01% $77,001,000 3 qtrs
VIKING GLOBAL INVESTORS LP Reduced 27,084,126 -23,971,018 0.29% $64,460,000 4 qtrs
Nikko Asset Management Americas Inc Added 21,858,173 +6,937,185 0.65% $52,678,000 4 qtrs
Sumitomo Mitsui Trust Holdings Inc New 21,858,173 +21,858,173 0.04% $52,022,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
CL A SHS

Voting authority reported

Sole
0
Shared
248,506
None
86,486,526

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.